Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Belgian biopharmaceutical company UCB has agreed to sell the rights to Delsym, an over-the-counter 12-hour liquid cough suppressant, to Adams Respiratory for an upfront $122 million.
Subscribe to our email newsletter
In addition to the one-time, upfront payment, UCB will also receive royalties for a period of five years based on sales and a standard manufacturing supply agreement with a ‘cost-plus’ structure.
“This transaction is another step taken by UCB in its strategy to focus on research-driven innovation and novel therapeutic solutions for severe and chronic diseases treated by specialist physicians,” said Roch Doliveux, CEO of UCB.
Delsym is made with a patented time-release formulation that allows the cough suppressant dextromethorphan to be available in the body over a 12-hour period.
The companies also announced that they have entered into a separate agreement for the licensing of the 12-hour liquid technology.